A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy. | KINSHIP-DCM (DAN-301 (KINSHIP-DCM))

Principal Investigator

Dr Betty Raman

Contact us

Email: cvm_nurses@cardiov.ox.ac.uk

IRAS number

1012888